Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hanmi Pharmaceutical Co., Ltd.

http://www.hanmipharm.com/

Latest From Hanmi Pharmaceutical Co., Ltd.

Korea Q4 Roundup: GC’s IVIG US Approval, SK Biopharm Turns Around

Aside from mixed earnings at major South Korean pharma firms, recent updates across the local industry have included the ongoing leadership dispute at Hanmi Group, the approval and reimbursement of Yuhan’s lazertinib as a first-line NSCLC therapy and the US approval of GC Biopharma’s immuno-globulin product.

South Korea Companies

Korean Vs Global Biopharma M&A Trends: How Different Are They?

A number of recent significant transactions in the South Korean biopharma space indicate some emerging trends as the sector develops and expands internationally. Scrip takes a look at the over-arching themes in M&A activity over the past few years and how these may differ from those being observed globally.

South Korea M & A

Hanmi's Merger Plan Could Spark Power Struggle In South Korea Pharma Sector

An unexpected merger between Korea's Hanmi Pharm Group and chemical group OCI may raise eyebrows in terms of likely synergies, but analysts are viewing the planned transaction positively in terms of future cash flow. However, resistance from some members of Hanmi's founder family may mean a possible leadership struggle at the pharma company.

Consumer M & A

Hanmi Announces Merger While Possible Power Struggle Surfaces

An unexpected merger between Korea's Hanmi Pharm Group and chemical group OCI may raise eyebrows in terms of likely synergies, but analysts are viewing the planned transaction positively in terms of future cash flow. However, resistance from some members of Hanmi's founder family may mean a possible leadership struggle at the pharma company.

South Korea M & A
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Beijing Hanmi Pharmaceutical Co., Ltd.
    • Hanmi Holdings Co., Ltd
UsernamePublicRestriction

Register